ZYXI INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Zynex (ZYXI) Investors with Substantial Losses to Contact Firm's Attorneys, Firm Investigating Delayed Earnings Report and Possible Securities Law Violations

Stock Information for Zynex Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zynex Inc.

Zynex Sets First Quarter 2024 Earnings Call
Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award
Zynex Reports Fourth Quarter and Full Year 2023 Financial Results
Zynex Introduces New Products
Sichenzia Ross Ference Carmel LLP Closes Over 100 Capital Markets Transactions Valued At Over $700 Million in 2023
Zynex Receives FDA Clearance for its Next Generation NMES Device
Zynex Recognized in Top 25 Medical Device Companies for 2024
Zynex to Participate at the Needham Annual Growth Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.